The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial.
Advanced cancer
Fatigue
Intervention
Pain
Quality of life
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Apr 2022
02 Apr 2022
Historique:
received:
27
08
2021
accepted:
25
11
2021
entrez:
3
4
2022
pubmed:
4
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Women with metastatic breast cancer (MBC) report debilitating physical and psychological symptoms, including fatigue, anxiety, and pain, that greatly impact their quality of life. Immersive virtual reality (VR) has been proposed as an adjunctive pain therapy for patients with cancer, and evidence suggests it may also decrease symptoms of anxiety and depression. The purpose of this pilot study was to assess whether VR should be pursued as a feasible and acceptable adjunctive therapy to alleviate physical and psychological symptoms in women with MBC. We conducted a pilot study testing the acceptability and efficacy of VR interventions with MBC patients to improve quality of life and to produce enduring decreases in fatigue, pain, depression, anxiety, and stress. Participants completed two different week-long VR experiences, reporting the prevalence of symptoms immediately before and after each study week, and 48 h later. Linear mixed models including fixed effects (VR intervention, counterbalancing order, and study week) and random effects (participant) were used to assess the effect of immersive VR on all outcome measures. Thirty-eight women with MBC completed the VR interventions and were included in analyses. Significant improvements post-intervention and/or 48 h later were demonstrated for quality of life, fatigue, pain, depression, anxiety, and stress. Across the entire study period, these differences met the criteria of a clinically important difference for quality of life, fatigue, depression, and stress. Participants reported feelings of relaxation and enjoyment and were highly likely to use the interventions gain. Our results demonstrate that VR experiences offer enduring benefits to the physical and psychological well-being of women with MBC. VR interventions are a feasible and acceptable intervention that can be conducted in a patient's own home. Such interventions are worthy of future investigation as a novel approach to improving quality of life in a patient population that have often been overlooked. Prospectively registered on 25th October 2019 with Australian New Zealand Clinical Trials Registry (ref: ACTRN12619001480178 ).
Sections du résumé
BACKGROUND
BACKGROUND
Women with metastatic breast cancer (MBC) report debilitating physical and psychological symptoms, including fatigue, anxiety, and pain, that greatly impact their quality of life. Immersive virtual reality (VR) has been proposed as an adjunctive pain therapy for patients with cancer, and evidence suggests it may also decrease symptoms of anxiety and depression. The purpose of this pilot study was to assess whether VR should be pursued as a feasible and acceptable adjunctive therapy to alleviate physical and psychological symptoms in women with MBC.
METHODS
METHODS
We conducted a pilot study testing the acceptability and efficacy of VR interventions with MBC patients to improve quality of life and to produce enduring decreases in fatigue, pain, depression, anxiety, and stress. Participants completed two different week-long VR experiences, reporting the prevalence of symptoms immediately before and after each study week, and 48 h later. Linear mixed models including fixed effects (VR intervention, counterbalancing order, and study week) and random effects (participant) were used to assess the effect of immersive VR on all outcome measures.
RESULTS
RESULTS
Thirty-eight women with MBC completed the VR interventions and were included in analyses. Significant improvements post-intervention and/or 48 h later were demonstrated for quality of life, fatigue, pain, depression, anxiety, and stress. Across the entire study period, these differences met the criteria of a clinically important difference for quality of life, fatigue, depression, and stress. Participants reported feelings of relaxation and enjoyment and were highly likely to use the interventions gain.
CONCLUSIONS
CONCLUSIONS
Our results demonstrate that VR experiences offer enduring benefits to the physical and psychological well-being of women with MBC. VR interventions are a feasible and acceptable intervention that can be conducted in a patient's own home. Such interventions are worthy of future investigation as a novel approach to improving quality of life in a patient population that have often been overlooked.
TRIAL REGISTRATION
BACKGROUND
Prospectively registered on 25th October 2019 with Australian New Zealand Clinical Trials Registry (ref: ACTRN12619001480178 ).
Identifiants
pubmed: 35366823
doi: 10.1186/s12885-021-09081-z
pii: 10.1186/s12885-021-09081-z
pmc: PMC8976512
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
360Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
J Cyber Ther Rehabil. 2009 Spring;2(1):27-33
pubmed: 20390047
J Natl Cancer Inst. 2003 Aug 6;95(15):1165-8
pubmed: 12902446
Support Care Cancer. 2016 Aug;24(8):3557-65
pubmed: 27022965
J Cell Physiol. 2016 Feb;231(2):275-87
pubmed: 26238976
Int J Environ Res Public Health. 2021 Aug 14;18(16):
pubmed: 34444332
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
BMC Cancer. 2016 Feb 19;16:129
pubmed: 26896237
J Natl Compr Canc Netw. 2008 May;6(5):448-55
pubmed: 18492460
JAMA Netw Open. 2021 Feb 1;4(2):e2033004
pubmed: 33570573
PLoS One. 2014 Mar 12;9(3):e91276
pubmed: 24621518
Psychol Assess. 2013 Dec;25(4):1103-10
pubmed: 23730826
Clin J Pain. 2008 May;24(4):299-304
pubmed: 18427228
Eur J Oncol Nurs. 2021 Feb;50:101886
pubmed: 33321461
Behav Res Ther. 1995 Mar;33(3):335-43
pubmed: 7726811
Cancer. 2002 Jan 15;94(2):528-38
pubmed: 11900238
Psychooncology. 2019 Jul;28(7):1394-1407
pubmed: 31077475
Psychosom Med. 2002 Jul-Aug;64(4):604-11
pubmed: 12140350
Support Care Cancer. 2013 Jul;21(7):1893-9
pubmed: 23411998
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 27464353
Patient. 2017 Dec;10(6):719-727
pubmed: 28432593
Psychosomatics. 2018 May - Jun;59(3):251-258
pubmed: 29525523
Support Care Cancer. 2011 Apr;19(4):555-64
pubmed: 20336327
Oncol Nurs Forum. 2004 Jan-Feb;31(1):81-8
pubmed: 14722591
Sleep Med Clin. 2008 Mar;3(1):61-71
pubmed: 18769530
Biometrics. 1997 Sep;53(3):983-97
pubmed: 9333350
PLoS One. 2016 Dec 20;11(12):e0167523
pubmed: 27997539
J Med Syst. 2000 Jun;24(3):173-82
pubmed: 10984871
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Psychol Rep. 2018 Jun;121(3):548-565
pubmed: 28836917
Clin J Pain. 2001 Sep;17(3):229-35
pubmed: 11587113
J Stomatol Oral Maxillofac Surg. 2018 Sep;119(4):257-261
pubmed: 29317347
J Pain Symptom Manage. 2012 Apr;43(4):747-58
pubmed: 22088804
West J Nurs Res. 2008 Mar;30(2):181-96
pubmed: 17607053
Support Care Cancer. 2013 Jan;21(1):263-70
pubmed: 22688373